# ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

> **NCT05014464** · PHASE2 · RECRUITING · sponsor: **Hunan Province Tumor Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Crizotinib

## Key facts

- **NCT ID:** NCT05014464
- **Lead sponsor:** Hunan Province Tumor Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-11-13
- **Primary completion:** 2026-06-01
- **Final completion:** 2027-08-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014464, "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05014464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*